Athyrium Capital Management LP
Athyrium Capital Management is a specialized asset management company focusing on investment opportunities in the global healthcare sector.
Business Model:
Revenue: $8.8M
Employees: 2-10
Rankings
Industries / Tags:
Detailed Athyrium Capital Management LP Information
Geographic Data
Address: 530 Fifth Avenue 25th Floor
City: New York
State: NY
Zip: 10036
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$4B
Social
Linkedin
Crunchbase
Metrics
2,829,304Website Global Rank
6,044Website Monthly Traffic
Twitter Followers
Description
**Note: CrunchBase does not maintain a complete list of the investments made by the Athyrium funds. Please see our website at www.athyrium.com for a complete list of these investments.** Athyrium Capital Management, LP (“Athyrium”) is a specialized asset management company formed in 2008 to focus on investment opportunities in the global healthcare sector. Athyrium is a registered investment adviser under Section 203 of the Investment Advisers Act of 1940. The Athyrium team has substantial investment experience in the healthcare sector across a wide range of asset classes including public equity, private equity, fixed income, royalties, and other structured securities. Athyrium invests across all healthcare verticals including biopharma, medical devices and products, and healthcare services. The team partners with management teams to implement creative financing solutions to companies’ capital needs. Athyrium advises funds with over $1.7 billion of committed capital. We value our investors and are thankful for the trust they have placed in us. Our investors consist of public and corporate pension funds, charitable endowments, insurance companies, funds-of-funds, family offices, university endowments, and sovereign wealth funds.
Contact Phone:
+12124026925
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 9/2012 | BioFire Diagnostics | Venture Round | 25M |
| 7/2021 | Puma Biotechnology | Post-IPO Debt | 125M |
| 7/2013 | TRIA Beauty | Private Equity Round | 0 |
| 5/2022 | uMotif | Series B | 0 |
| 2/2018 | Veloxis | Post-IPO Debt | 60M |
| 11/2017 | Recro Pharma | Post-IPO Debt | 100M |
| 7/2018 | Agendia | Private Equity Round | 35M |
| 3/2022 | Puma Biotechnology | Post-IPO Equity | 10M |
| 5/2013 | BioFire Diagnostics | Venture Round | 45M |
| 12/2012 | Verenium | Debt Financing | 22.5M |
| 8/2016 | Medicrea | Post-IPO Equity | 22.6M |
| 3/2015 | Apollo Endosurgery | Debt Financing | 50M |
| 11/2017 | Progenity | Series B | 125M |
| 5/2014 | Travere Therapeutics | Post-IPO Equity | 46M |
| 9/2022 | Basilea Pharmaceutica | Post-IPO Debt | 76.8M |
| 12/2015 | Clover Health | Series B | 35M |
| 11/2013 | InnoPharma, Inc. | Debt Financing | 20M |
| 7/2013 | TRIA Beauty | Debt Financing | 45M |
| 1/2018 | VillageMD | Private Equity Round | 80M |
| 7/2019 | ArisGlobal | Private Equity Round | - |
| 10/2021 | Osmotica Pharmaceutical | Post-IPO Debt | 100M |
| 1/2016 | Halozyme Therapeutics | Post-IPO Debt | 150M |
| 3/2013 | SynCardia Systems | Debt Financing | 15M |
| 3/2019 | Secura Bio | Debt Financing | 90M |
| 2/2014 | Pernix Therapeutics | Post-IPO Debt | 65M |
| 12/2020 | BioCryst Pharmaceuticals | Post-IPO Debt | 0 |
| 1/2018 | OptiNose | Post-IPO Debt | 100M |
| 6/2018 | Water&s;s Edge Dermatology | Private Equity Round | - |
| 9/2016 | Pharmaceutics International | Private Equity Round | 0 |
| 3/2022 | Revance Therapeutics | Post-IPO Debt | 300M |
| 12/2014 | Zealand Pharma | Post-IPO Equity | 50M |
| 12/2018 | Dermira | Post-IPO Debt | 125M |
| 12/2013 | SynCardia Systems | Funding Round | 0 |
| 7/2014 | Travere Therapeutics | Post-IPO Debt | 45M |
| 3/2019 | Portola Pharmaceuticals | Post-IPO Debt | 125M |
| 6/2018 | Sound Physicians | Private Equity Round | 0 |
| 3/2019 | Recro Pharma | Post-IPO Debt | 40.5M |
| 9/2015 | Clover Health | Series A | 100M |
| 10/2018 | Kala Pharmaceuticals | Post-IPO Equity | 110M |
| 5/2022 | uMotif | Series B | 0 |
| 3/2022 | Revance Therapeutics | Post-IPO Debt | 0 |
| 3/2022 | Puma Biotechnology | Post-IPO Equity | 0 |
| 10/2021 | Osmotica Pharmaceutical | Post-IPO Debt | 0 |
| 7/2021 | Puma Biotechnology | Post-IPO Debt | 0 |
| 12/2020 | BioCryst Pharmaceuticals | Post-IPO Debt | 0 |
| 7/2019 | ArisGlobal | Private Equity Round | - |
| 3/2019 | Secura Bio | Debt Financing | 0 |
| 3/2019 | Portola Pharmaceuticals | Post-IPO Debt | 0 |
| 3/2019 | Recro Pharma | Post-IPO Debt | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
